Professor Anna Kirby

Professor Anna Kirby is a Consultant Clinical Oncologist at Icon Cancer Centre London, specialising in the treatment of breast cancer. She graduated from Cambridge University in 1995 with a first-class honours degree in Medicine and Psychology and completed her medical qualifications at Cambridge University Medical School in 1997.  

Professor Kirby completed her general medical training at St George’s Hospital, London, followed by specialist oncology training at The Royal Marsden and Guy’s and St Thomas’ Hospitals. She undertook research into breast radiotherapy as part of an MD program at The Royal Marsden and The Institute of Cancer Research between 2007 and 2009. Her publications have addressed methods of improving the accuracy of breast radiotherapy delivery to reduce side-effects of treatment and also the development and implementation of heart-sparing breast radiotherapy techniques as a national standard of care. Professor Kirby is Chief Investigator of the FAST-Forward Boost Trial, Technical Radiotherapy Lead for the PARABLE Proton Trial, and Breast Lead on the CORE trial evaluating the role of stereotactic radiotherapy in treating metastatic disease. 

Professor Kirby is committed to providing personalised care for her patients, utilising the latest research and advanced techniques in breast cancer radiotherapy. 

Alongside her clinical practice, Professor Kirby was President of the European Society of Radiation Oncology (ESTRO) from 2022-24 and remains a member of the ESTRO Board.

Other posts held

Royal Marsden (Sutton and Chelsea) 

GMC: 4127194

• Partial breast radiotherapy for women with early breast cancer (UK IMPORT LOW Trial): 10-year outcomes from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Kirby AM, Finneran L, Griffin C, et al. Accepted 2025 to Lancet Oncology. https://doi.org/10.1016/S1470-2045(25)00194-9.

• Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Coles CE, Haviland JS, Kirby AM, et al. Lancet. 2023 Jun 24;401(10394):2124-2137. doi: 10.1016/S0140-6736(23)00619-0. PMID: 37302395.

• Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit? Nagpal SK, Khabra K, Ross G, Kirby AM. Clin Oncol (R Coll Radiol). 2023 Nov;35(11):736-743. doi: 10.1016/j.clon.2023.08.006. PMID: 37684189.

• A Randomised Phase II Clinical Trial Comparing the Deliverability and Acute Toxicity of Wide Tangent versus Volumetric Modulated Arc Therapy to the Breast and Internal Mammary Chain. Ranger A, Dunlop A, Hansen VN, Princewill G, Landeg S, Donovan EM, Harris EJ, McNair HA, Haviland J, Kirby AM. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):526-533. doi: 10.1016/j.clon.2022.03.020. PMID: 35597698.

• Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study. Thiruchelvam PTR, Leff DR, Godden AR, Cleator S, Wood SH, Kirby AM, et al. Lancet Oncol. 2022 May;23(5):682-690. doi: 10.1016/S1470-2045(22)00145-0. Epub 2022 Apr 7. PMID: 35397804; PMCID: PMC9630150.